Revance Therapeutics (NASDAQ:RVNC) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

Several other analysts also recently commented on the stock. Mizuho restated a “buy” rating and set a $54.00 price objective on shares of Revance Therapeutics in a research report on Friday, January 5th. Cowen set a $55.00 price objective on shares of Revance Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 17th. Guggenheim downgraded shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Zacks Investment Research upgraded shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 6th. Finally, Needham & Company LLC initiated coverage on shares of Revance Therapeutics in a research report on Monday, March 26th. They set a “buy” rating and a $42.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Revance Therapeutics has an average rating of “Buy” and an average price target of $44.67.

RVNC opened at $30.60 on Friday. The company has a market capitalization of $1,225.03, a price-to-earnings ratio of -7.63 and a beta of 1.33. Revance Therapeutics has a 1-year low of $18.42 and a 1-year high of $37.45.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.99) by ($0.15). The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.09 million. Revance Therapeutics had a negative net margin of 46,025.57% and a negative return on equity of 64.40%. The firm’s revenue for the quarter was down 50.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.95) earnings per share. sell-side analysts predict that Revance Therapeutics will post -3.56 EPS for the current fiscal year.

In related news, CFO Lauren P. Silvernail sold 25,867 shares of the firm’s stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $34.50, for a total transaction of $892,411.50. Following the completion of the transaction, the chief financial officer now directly owns 98,821 shares of the company’s stock, valued at $3,409,324.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO L Daniel Browne sold 27,283 shares of the firm’s stock in a transaction on Wednesday, March 7th. The shares were sold at an average price of $31.43, for a total transaction of $857,504.69. Following the transaction, the chief executive officer now directly owns 131,208 shares of the company’s stock, valued at $4,123,867.44. The disclosure for this sale can be found here. Insiders have sold 98,366 shares of company stock valued at $3,182,947 over the last ninety days. 18.86% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new position in Revance Therapeutics during the third quarter valued at $144,000. Cowen Inc. purchased a new position in Revance Therapeutics during the fourth quarter valued at $225,000. Teacher Retirement System of Texas purchased a new position in Revance Therapeutics during the fourth quarter valued at $255,000. Quinn Opportunity Partners LLC purchased a new position in Revance Therapeutics during the fourth quarter valued at $325,000. Finally, Two Sigma Advisers LP purchased a new position in Revance Therapeutics during the fourth quarter valued at $343,000. 95.01% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2018/04/22/revance-therapeutics-rvnc-stock-rating-upgraded-by-bidaskclub.html.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.